Ms. Emily Williams reports

SATELLOS BIOSCIENCE ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS

Satellos Bioscience Inc. has released the results of its annual meeting of shareholders, held June 17, 2026.

All the nominees listed in the management information circular dated May 14, 2026, were elected as directors. Shareholders present at the meeting or represented by proxy totalled 55.3 per cent of the issued and outstanding common shares of the company.

The results of the vote are detailed in the attached table.

Satellos shareholders also voted in favour of the reappointment of PricewaterhouseCoopers LLP as the auditor of the company.

Please refer to circular available on SEDAR+ and EDGAR for more details on the matters covered at the meeting. Final voting results on all matters voted on at the meeting will also be filed on SEDAR+ and EDGAR.

About Satellos Bioscience Inc.

Satellos is a clinical-stage drug development company advancing SAT-3247, a first-of-its-kind, orally administered small molecule therapy designed to reset the body's natural muscle repair and regeneration process in degenerative muscle diseases. SAT-3247 is being evaluated as a potential disease-modifying treatment, initially for DMD, in two phase II clinical trials: Basecamp in pediatrics and Trailhead in adults. SAT-3247 targets AAK1, a protein that is a key regulator of the body's natural muscle repair and regeneration biology, which Satellos discovered is disrupted in DMD and other degenerative conditions. By inhibiting AAK1, SAT-3247 is designed to re-establish a critical biochemical signal needed to guide this process, in a dystrophin-independent manner. This mechanistic feature offers SAT-3247 the potential for broad applicability as either a stand-alone treatment to potentially enhance muscle and function, or as adjunctive therapy alongside other approaches. Satellos has identified additional degenerative muscle diseases where enhancing muscle repair and regeneration may have therapeutic benefit, and plans to pursue these opportunities in future clinical development.

We seek Safe Harbor.